You searched for "regenerative"
PREVIEW: RCOphth Annual Congress 2025 #EyeConUK
That time of year is coming around again and the ophthalmic community are ironing their ties and polishing their shoes ready for the Royal College of Ophthalmologists’ Annual #EyeConUK Congress 2025, taking place at the ACC, Liverpool, between 19–22 May....Traumatic optic neuropathy
In neuro-ophthalmology we get asked a lot about management of patients who suffered significant trauma and presented with loss of vision secondary to presumed traumatic optic neuropathy (TON). TON happens usually in the context of significant craniofacial trauma. The incidence...SEEN by Joshua
They were all SEEN by one individual who then took their story to the world to witness. He saw them through his eyes and captured them in his camera lens. Through his vision and through their visual interpretations, an extraordinary,...
Injection of methotrexate into silicone oil-filled eyes for grade C PVR
Methotrexate (MTX) is an antineoplastic antimetabolite with immunosuppressant properties. Folate antagonism is known to contribute to the antiproliferative effects of MTX, and release of adenosine from cells and inhibition of polyamines may explain its anti-inflammatory effects. These activities contribute to...
Neighbourhood deprivation and risk of age-related eye diseases
In this large epidemiological study, the authors sought to determine if neighbourhood wealth affects age-related ocular health. In particular they wished to see if there was a correlation between social deprivation and macular degeneration, cataract, diabetes-related eye complications, and glaucoma....
OCT positioning regimen in macular hole surgery
The authors set out to evaluate an OCT-based positioning regimen for macular hole surgery. Patients were advised to maintain prone positioning until the hole was confirmed to be closed based on daily OCTs. Surgery consisted of 23-gauge phacovitrectomy with internal...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Atrophy and anti-VEGF
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
Corneal crosslinking in pellucid marginal degeneration
Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
